1
00:00:03,560 --> 00:00:12,700
a key driver of malignant transformation

2
00:00:12,700 --> 00:00:15,469
tumor maintenance and resistance to

3
00:00:15,469 --> 00:00:18,200
therapy is the impairment of a critical

4
00:00:18,200 --> 00:00:20,870
cellular function a puto --ss or

5
00:00:20,870 --> 00:00:26,450
programmed cell death abt 199 or GDC

6
00:00:26,450 --> 00:00:29,840
zero 199 is a small molecule designed to

7
00:00:29,840 --> 00:00:32,689
selectively bind and inhibit bcl-2 a

8
00:00:32,689 --> 00:00:35,890
critical regulator of a puto psious

9
00:00:35,890 --> 00:00:38,839
bcl-2 is a member of a larger family of

10
00:00:38,839 --> 00:00:41,390
structurally related proteins that are

11
00:00:41,390 --> 00:00:44,480
either pro a photonic or anti a photonic

12
00:00:44,480 --> 00:00:47,089
the dynamic balance between anti a

13
00:00:47,089 --> 00:00:50,390
patata members such as bcl-2 and pro a

14
00:00:50,390 --> 00:00:52,760
patata family members can determine

15
00:00:52,760 --> 00:00:55,879
whether a cell lives or dies by binding

16
00:00:55,879 --> 00:00:57,829
common structures shared among pro a

17
00:00:57,829 --> 00:01:01,579
patata family members bcl-2 inhibits a

18
00:01:01,579 --> 00:01:06,200
puto --ss in response to stress normal

19
00:01:06,200 --> 00:01:08,570
cells as well as certain cancer cells

20
00:01:08,570 --> 00:01:11,180
will up regulate pro a patata family

21
00:01:11,180 --> 00:01:13,820
members in normal cells this increased

22
00:01:13,820 --> 00:01:16,310
expression of pro a patata proteins is

23
00:01:16,310 --> 00:01:20,240
sufficient to induce a puto sious in

24
00:01:20,240 --> 00:01:22,579
contrast malignant cells will often

25
00:01:22,579 --> 00:01:25,549
express more bcl-2 to keep pro a patata

26
00:01:25,549 --> 00:01:28,490
kembers in check this prevents cancer

27
00:01:28,490 --> 00:01:30,680
cells from eliciting and a patata chrous

28
00:01:30,680 --> 00:01:31,899
Ponce

29
00:01:31,899 --> 00:01:34,909
although increased bcl-2 expression

30
00:01:34,909 --> 00:01:36,979
allows the cancer cell to survive under

31
00:01:36,979 --> 00:01:39,829
continual metabolic stress the reserve

32
00:01:39,829 --> 00:01:41,780
of pro a patata family members

33
00:01:41,780 --> 00:01:44,270
sequestered by bcl-2 can leave those

34
00:01:44,270 --> 00:01:47,890
cells vulnerable to cell death

35
00:01:47,979 --> 00:01:51,770
co-developed by AB V and Genentech 199

36
00:01:51,770 --> 00:01:54,109
is an orally available small molecule

37
00:01:54,109 --> 00:01:56,719
designed to selectively bind and inhibit

38
00:01:56,719 --> 00:02:02,479
bcl-2 upon binding bcl-2 199 can

39
00:02:02,479 --> 00:02:04,340
displace the store of pro a patata

40
00:02:04,340 --> 00:02:07,399
proteins in malignant cells this causes

41
00:02:07,399 --> 00:02:09,350
a shift in the dynamic balance between

42
00:02:09,350 --> 00:02:11,220
the available bcl-2

43
00:02:11,220 --> 00:02:14,670
and pro a patata family members inducing

44
00:02:14,670 --> 00:02:18,300
a puto sious with bcl-2 inhibited by

45
00:02:18,300 --> 00:02:21,540
$1.99 pro a patata proteins are left

46
00:02:21,540 --> 00:02:23,610
free to promote poor formation in the

47
00:02:23,610 --> 00:02:26,550
mitochondria signaling a point of no

48
00:02:26,550 --> 00:02:27,000
return

49
00:02:27,000 --> 00:02:31,920
for the cell cytochrome C and other

50
00:02:31,920 --> 00:02:34,140
factors are subsequently released from

51
00:02:34,140 --> 00:02:37,140
the mitochondria initiating the caspase

52
00:02:37,140 --> 00:02:40,740
activation cascade the activation of

53
00:02:40,740 --> 00:02:43,260
these proteolytic enzymes coordinates

54
00:02:43,260 --> 00:02:45,360
the ordered destruction of the cancer

55
00:02:45,360 --> 00:02:51,390
cell app-v and Genentech are continuing

56
00:02:51,390 --> 00:02:53,880
their research into the selective bcl-2

57
00:02:53,880 --> 00:03:00,830
inhibitor ABT 199 or GDC 0 199
